Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Cancer in Slovenia 2015 Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of republic of Slovenia; 2018.LjubljanaInstitute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of republic of Slovenia2018Search in Google Scholar
Schmoll1 HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516. doi: 10.1093/annonc/mds236Schmoll1HJVan CutsemESteinAValentiniVGlimeliusBHaustermansKESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making201223247951610.1093/annonc/mds236Open DOISearch in Google Scholar
Van Cutsem1 E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 1386-422. doi: 10.1093/annonc/mdw235VanCutsem1 ECervantesAAdamRSobreroAVanKrieken JHAderkaDESMO consensus guidelines for the management of patients with metastatic colorectal cancer2016138642210.1093/annonc/mdw235Open DOISearch in Google Scholar
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer. V.2.2018. [cited 2018 Jun 15]. Available at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdfNational Comprehensive Cancer Network[cited 2018 Jun 15]. Available athttp://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdfSearch in Google Scholar
National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: rectal cancer. V.2.2018 [cited 2018 Aug 3]. Available at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdf[cited 2018 Aug 3]. Available athttp://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdfSearch in Google Scholar
Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. A systemic review and meta-analysis. JAMA 2011; 305: 233542. doi: 10.1001/jama.2011.749BiagiJJRaphaelMJMackillopWJKongWKingWDBoothCMAssociation between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. A systemic review and meta-analysis201130523354210.1001/jama.2011.749Open DOISearch in Google Scholar
Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8. doi: 10.2478/v10019-009-0004-1OcvirkJAdvances in the treatment of metastatic colorectal carcinoma2009431810.2478/v10019-009-0004-1Open DOISearch in Google Scholar
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl Med 2005; 352: 476-87. doi: 10.1053/j.gastro.2008.02.098MeyerhardtJAMayerRJSystemic therapy for colorectal cancer20053524768710.1053/j.gastro.2008.02.098Open DOISearch in Google Scholar
Esin E, Yalcin S. Maintenance strategy in metastatic colorectal cancer: a systematic review. Cancer Treat Rev 2016; 42: 82-90. doi: 10.1016/j. ctrv.2015.10.012EsinEYalcinSMaintenance strategy in metastatic colorectal cancer: a systematic review201642829010.1016/jctrv.2015.10.012Open DOISearch in Google Scholar
Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment. Ann Oncol 2010; 21: v93- 7. doi: 10.1093/annonc/mdq222Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment201021v93710.1093/annonc/mdq222Open DOISearch in Google Scholar
Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60. doi: 10.1056/NEJMra0804588MarkowitzSDBertagnolliMMMolecular basis of colorectal cancer200936124496010.1056/NEJMra0804588Open DOISearch in Google Scholar
De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812- 20. doi: 10.1001/jama.2010.1535De RoockWJonkerDJDiNicolantonio FSartore-BianchiATuDSienaSLambaSAssociation of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab201030418122010.1001/jama.2010.1535Open DOISearch in Google Scholar
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62. doi: 10.1016/S1470-2045(10)70130-3De RoockWClaesBBernasconiDDe SchutterJBiesmansBFountzilasGEffect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis2010117536210.1016/S1470-2045(10)70130-3Open DOISearch in Google Scholar
Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99. doi: 10.3978/j.issn.2078-6891.2015.077TolJNagtegaalIDPuntCJABRAF mutation in metastatic colorectal cancer2009361989910.3978/j.issn.2078-6891.2015.077Open DOISearch in Google Scholar
Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite- stable colon cancer. Caner Res 2005; 65: 6063-9. doi: 10.1158/0008-5472.CAN-05-0404SamowitzWSSweeneyCHerrickJAlbertsenHLevinTRMurtaughMAPoor survival associated with the BRAF V600E mutation in microsatellite- stable colon cancer2005656063910.1158/0008-5472.CAN-05-0404Open DOISearch in Google Scholar
Ličar A, Cerkovnik P, Novaković S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 2011; 28: 1048-53. doi: 10.1007/s12032-010-9631-zLičarACerkovnikPNovakovićSDistribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer20112810485310.1007/s12032-010-9631-zOpen DOISearch in Google Scholar
Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-402. doi: 10.1093/annonc/mdq258Fariña-SarasquetaAvan LijnschotenGMoerlandECreemersGJLemmensVERuttenHJThe BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients201021239640210.1093/annonc/mdq258Open DOISearch in Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi: 10.1016/j.ejca.2008.10.026EisenhauerEATherassePBogaertsJSchwartzLHSargentDFordRNew response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)2009452284710.1016/j.ejca.2008.10.026Open DOISearch in Google Scholar
Marzouk O, Schofield J. Review of histopathological and molecular prognostic features in colorectal cancer. Cancers 2011; 3: 276-81. doi: 10.3390/cancers3022767MarzoukOSchofieldJReview of histopathological and molecular prognostic features in colorectal cancer201132768110.3390/cancers3022767Open DOISearch in Google Scholar
Ličar A, Cerkovnik P, Ocvirk J, Novaković S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol 2010; 36: 1137-44. doi: 10.3892/ijo_00000596.LičarACerkovnikPOcvirkJNovakovićS.KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment20103611374410.3892/ijo_00000596Open DOISearch in Google Scholar
Artale S, Sartore- Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217- 9. doi: 10.1200/JCO.2008.18.7266ArtaleSSartore-Bianchi AVeroneseSMGambiVSarnataroCSGambacortaMMutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer2008264217910.1200/JCO.2008.18.7266Open DOISearch in Google Scholar
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 146675. doi: 10.1016/j.ejca.2012.02.057BokemeyerCVanCutsem ERougierPCiardielloFHeegerSSchlichtingMAddition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials20124814667510.1016/j.ejca.2012.02.057Open DOISearch in Google Scholar
Artale S, Sartore- Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-9. doi: 10.1200/JCO.2008.18.7286ArtaleSSartore-Bianchi AVeroneseSMGambiVSarnataroCSGambacortaMMutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer2008264217910.1200/JCO.2008.18.7286Open DOISearch in Google Scholar
Rebersek M, Boc M, Škerl P, Benedik J, Hlebanja Z, Volk N, et al. Efficacy of first- line systemic treatment in correlation with BRAF V600E and different KRAS mutations colorectal cancer - a single institution retrospective analysis. Radiol Oncol 2011; 45: 285-91. doi: 10.2478/v10019-011-0039-yRebersekMBocMŠkerlPBenedikJHlebanjaZVolkNEfficacy of first- line systemic treatment in correlation with BRAF V600E and different KRAS mutations colorectal cancer - a single institution retrospective analysis2011452859110.2478/v10019-011-0039-yOpen DOISearch in Google Scholar
Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, et al. The role of KRAS, BRAF, NRAS and PIK3CA mutations as a markers of resistance of cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol 2009; 27: 9020. doi: 10.1158/1078-0432.CCR-08-2961LambrechtsDDe RoockWPrenenHDe SchutterJJacobsBBiesmansBThe role of KRAS, BRAF, NRAS and PIK3CA mutations as a markers of resistance of cetuximab in chemorefractory metastatic colorectal cancer200927902010.1158/1078-0432.CCR-08-2961Open DOISearch in Google Scholar
Tejpar S, De Roock W. PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated With EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium[abstract]. Eur J Cancer Suppl 2009; 7: 322. No. 6005TejparSDeRoock W.PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated With EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium[abstract]200973226005Search in Google Scholar
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-21. doi: 10.18632/oncotarget.13697LoupakisFRuzzoACremoliniCVincenziBSalvatoreLSantiniDKRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer20091017152110.18632/oncotarget.13697Open DOISearch in Google Scholar
Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-7. doi: 10.1200/JCO.2012.42.2592TejparSCelikISchlichtingMSartoriusUBokemeyerCVan Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab2012303570710.1200/JCO.2012.42.2592Open DOISearch in Google Scholar
Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-65. doi: 10.1200/JCO.2012.45.1492. Epub 2012 Nov 26.PeetersMDouillardJYVanCutsem ESienaSZhangKWilliamsRMutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab2013317596510.1200/JCO.2012.45.1492Epub 2012 Nov 26Open DOISearch in Google Scholar
Roth AD, Tejpar S, Dolorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010: 28: 466-74. doi: 10.1200/JCO.2009.23.3452.RothADTejparSDolorenziMYanPFioccaRKlingbielDPrognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial2010284667410.1200/JCO.2009.23.3452Open DOISearch in Google Scholar
Fujiyoshi K, Yamamoto G, Takahashi A, Arai Y, Yamada M, Kakuta M, et al. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep 2017; 37: 785-92. doi: 10.3892/or.2016.5323.FujiyoshiKYamamotoGTakahashiAAraiYYamadaMKakutaMHigh concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases2017377859210.3892/or.2016.5323Open DOISearch in Google Scholar
Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94: 76-81. doi: 10.1016/j. radonc.2009.10.001GaedckeJGradeMJungKSchirmerMJoPObermeyerCKRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy201094768110.1016/jradonc.2009.10.001Open DOISearch in Google Scholar
Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2015; 96: 156-66. doi: 10.1016/j.critrevonc.2015.05.016PietrantonioFCremoliniCPetrelliFDiBartolomeo MLoupakisFMaggiCFirst-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis2015961566610.1016/j.critrevonc.2015.05.016Open DOISearch in Google Scholar
Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26: 13-21. doi: 10.1093/annonc/mdu378SorichMJWieseMDRowlandAKichenadasseGMcKinnonRAKarapetisCSExtended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials201526132110.1093/annonc/mdu378Open DOISearch in Google Scholar
Scartozzi M, Galizia E, Chiorrini S, Giampieri G, Berardi R, Pieratoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer treated with first- line bevacizumab. Clin Oncol 2009; 20: 227-30. doi: 10.1093/annonc/mdn637ScartozziMGaliziaEChiorriniSGiampieriGBerardiRPieratoniCArterial hypertension correlates with clinical outcome in colorectal cancer treated with first- line bevacizumab2009202273010.1093/annonc/mdn637Open DOISearch in Google Scholar
Mir O, Ropert S, Alexandre J, Goldwasser F. Hypertension as a surrogate marker for the activity of anti- VEGF agents. Ann Oncol 2009; 20: 967-70. doi: 10.1093/annonc/mdp206MirORopertSAlexandreJGoldwasserFHypertension as a surrogate marker for the activity of anti- VEGF agents2009209677010.1093/annonc/mdp206Open DOISearch in Google Scholar
Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, et al. Effect of renal impairment on the pharmacokinetics and tolarebility of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49: 225-34. doi: 10.1007/s00280-001-4808-0PooleCGardinerJTwelvesCJohnstonPHarperPCassidyJEffect of renal impairment on the pharmacokinetics and tolarebility of capecitabine (Xeloda) in cancer patients2002492253410.1007/s00280-001-4808-0Open DOISearch in Google Scholar
Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-75. doi: 10.1200/JCO.2001.19.21.4097CassidyJTwelvesCVanCutsem EHoffPBajettaEBoyerMFirst-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin2002135667510.1200/JCO.2001.19.21.4097Open DOISearch in Google Scholar
Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1* 28 genotype and irinotecan- induced neutropenia: dose matters. J Nati Cancer Inst 2007; 99: 1290-421. doi: 10.1200/JCO.2009.21.7943HoskinsJMGoldbergRMQuPIbrahimJGMcLeodHLUGT1A1* 28 genotype and irinotecan- induced neutropenia: dose matters200799129042110.1200/JCO.2009.21.7943Open DOISearch in Google Scholar
Hoskins JM, McLeod HL. UGT1A and irinotecan toxicity: keeping it in the family. J Clin Oncol 2009; 27: 2419-21. doi: 10.2217/pgs.10.95HoskinsJMMcLeodHLUGT1A and irinotecan toxicity: keeping it in the family20092724192110.2217/pgs.10.95Open DOISearch in Google Scholar
Pereg D, Lishner M. Bevacizumab treatment for cancer treatment with cardiovascular disease: a double edged sword? Eur Heart J 2008; 29: 2325-26. doi: 10.1093/eurheartj/ehn384.PeregDLishnerMBevacizumab treatment for cancer treatment with cardiovascular disease: a double edged sword?20082923252610.1093/eurheartj/ehn384Open DOISearch in Google Scholar
Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. J Nati Cancer Inst 2007; 1232-9. 0.1093/jnci/djm086ScappaticciFASkillingsJRHoldenSNGerberHPMillerKKabbinavarFArterial thromboembolic events in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab2007123290.1093/jnci/djm086Open DOISearch in Google Scholar
Lee CS, Ryan EJ, Glen A Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol 2014; 20: 3751-61. doi: 10.3748/wjg.v20.i14.3751LeeCSRyanEJGlen A Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation20142037516110.3748/wjg.v20.i14.3751Open DOISearch in Google Scholar
Ocvirk J, Rebersek M. Management of cutaneous side effect of cetuximab therapy with K1 creme. Radiol Oncol 2008; 42: 215-24. doi: 10.2478/v10019-008-0022-4OcvirkJRebersekMManagement of cutaneous side effect of cetuximab therapy with K1 creme2008422152410.2478/v10019-008-0022-4Open DOISearch in Google Scholar
Ocvirk J, Cencelj S. Management of cutaneous side-effect of cetuximab therapy in patients with metastatic colorectal cancer. JEADV 2010; 24: 4539. doi: 10.1111/j.1468-3083.2009.03446.xOcvirkJCenceljSManagement of cutaneous side-effect of cetuximab therapy in patients with metastatic colorectal cancer201024453910.1111/j.1468-3083.2009.03446.xOpen DOISearch in Google Scholar
Ocvirk J, Rebersek M, Boc M, Mesti T, Ebert Moltara M. Prophylactic use of K1 crem for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2016; 28(15 Suppl): V124. doi: 10.1200/jco.2010.28.15_suppl.e14011.OcvirkJRebersekMBocMMestiTEbert Moltara M. Prophylactic use of K1 crem for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC)20162815 SupplV12410.1200/jco.2010.28.15_suppl.e14011Open DOISearch in Google Scholar
Siena S, Glynne-Jones R, Adenis A, Thaler J, Preusser P, Aguilar EA, et al. Reduced incidence of infusion- related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamin premedication. Cancer 2010, 116: 1827-37. doi: 10.1002/cncr.24945SienaSGlynne-JonesRAdenisAThalerJPreusserPAguilarEAReduced incidence of infusion- related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamin premedication201011618273710.1002/cncr.24945Open DOISearch in Google Scholar
Venderbosch, ID Nagtegaal, TS Maughan, CG Smith , JP Cheadle, D Fisher, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014 20: 5322-30. doi: 10.1158/1078-0432. CCR-14-0332VenderboschID NagtegaalMaughanTSSmithCGCheadleJPFisherDMismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies20142053223010.1158/1078-0432CCR-14-0332Open DOISearch in Google Scholar
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-20. doi: 10.1056/NEJMoa1500596LeDTUramJNWangHBartlettBRKemberlingHEyringADPD-1 blockade in tumors with mismatch-repair deficiency201537225092010.1056/NEJMoa1500596Open DOISearch in Google Scholar
Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014; 53: 852-64. doi: 10.3109/0284186X.201 4.895036TherkildsenCBergmannTKHenrichsen-SchnackTLadelundSNilbertMThe predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis2014538526410.3109/0284186X.2014.895036Open DOISearch in Google Scholar